LBCT Submission Period Open: Phase II and III Trials Must Have Significant Impact on Clinical Practice
ASN is accepting late-breaking clinical trials (LBCT) through September 1, 2021 (2:00 p.m. EDT) for Kidney Week 2021, which will include virtual content and an in-person annual meeting from Thursday, November 4, through Sunday, November 7, in San Diego, CA.
Submissions should discuss Phase II and III trials that will have significant impact on clinical practice. Clinical trials “are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions.
Some common reasons for conducting clinical studies include: Evaluating one or more interventions…for treating a disease, syndrome, or condition…Finding ways to prevent the initial development or recurrence of a disease or condition…Evaluating one or more interventions aimed at identifying or diagnosing a particular disease or condition…Examining methods for identifying a condition or risk factors for that condition…Exploring and measuring ways to improve the comfort and quality of life of people with a chronic illness through supportive care" (ClinicalTrials.gov).
ASN requires user logins and current disclosures for all authors at time of submission. A lead author must be assigned for each abstract submission. This individual is the first author listed in the submission and has the primary responsibility for communications with ASN.
For more information about LBCT submission requirements, visit bit.ly/3xTrLim. For more information about Kidney Week 2021, visit bit.ly/3rjg0j3.